Pfizer And Moderna Jabs 90% Effective After Two Doses In Real-World Study

Washington : Covid-19 vaccine from Pfizer and Moderna effectively prevented coronavirus infections, not just illness, with substantial protection evident two weeks after the first dose, government researchers said.

Two doses of the vaccines provide as much as 90% protection against infection, according to data from US Centers for Disease Control and Prevention study published on Monday. Earlier clinical trials had established that the shots also prevent illness, hospitalisations, and deaths.

The study adds to evidence that new vaccines made with messenger RNA technology actually reduce the spread of the virus in real-world conditions. An earlier study in Israel found a single dose of the Pfizer vaccine reduced infections by as much as 85%.

The CDC studied a group of about 4,000 front-line workers, including health-care personnel, first responders, teachers and service workers from mid-December to mid-March as vaccines rolled out widely. These groups were among the first to be vaccinated, along with the vulnerable elderly, because of their risk of exposure to the virus.

Participants were tested for Covid weekly and surveyed for reports of symptoms. The researchers compared the frequency of Covid infections before and after vaccinations to estimate how effective the shots were at preventing SARS-CoV-2 spread, regardless of whether people felt sick or not. Both the vaccines from Pfizer and partner BioNTech SE and Moderna require two doses spaced weeks apart. Two weeks after the first dose, the shots appeared to prevent 80% of infections; that rose to 90% two week..

The study included a mix of participants who were tested after developing symptoms as well as infections that were picked up by weekly tests when people were still feeling well. The results didn’t break out in detail the vaccine’s ability to prevent asymptomatic or minimally symptomatic infections.

  • Related Posts

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

    Pak-made illegal cosmetics recovered from Itwari shop

    Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Pak-made illegal cosmetics recovered from Itwari shop

    Pak-made illegal cosmetics recovered from Itwari shop

    Licences of 20 medical stores suspended after inspections

    Licences of 20 medical stores suspended after inspections

    Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

    Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    HP accounts for 47 inferior drugs in March alert

    HP accounts for 47 inferior drugs in March alert